OSSUR ICELAND EHF

OSSUR ICELAND EHF has been granted 185 US utility patents between 2016 and 2025, placing OSSUR ICELAND EHF at rank #2,131 across all assignees tracked by PlainPatent. This portfolio spans 31 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.9 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, OSSUR ICELAND EHF is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 54.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 139 grants, compared with 46 in the 2015–2019 window — a +202% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. OSSUR ICELAND EHF's 13.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 31 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark OSSUR ICELAND EHF against peers pursuing similar technology classes.